- AMAG Pharmaceuticals (AMAG +3.3%) is one of Summer Street's top picks for 2014.
- Analyst Carol Werther likes the risk reward profile: "We see 20% downside contained risk (first time ever cash flow positive Q3 2013 and cash $213M) versus upside toward our price target on positive result from FDA and a sales re-acceleration gastroenterology specific launch plan to target the ~150 IBD centers."
- Werther on Feraheme: "We assign a very high probability of January 2014 FDA approval."
- Price target is $43, representing upside of ~87% from Monday's close.
Summer Street sees big upside for AMAG Pharma
Dec 31 2013, 10:48 ET